A pharmacological and clinical review on Topiramate, a new antiepileptic drug

Pharmacological Research

Volumn 35, Issue 4, 1997, Pages 241-256

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Efficacy; Epilepsy; Pharmacokinetics; Pharmacology; Review; Side effects; Topiramate

Indexed keywords

AMPA RECEPTOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CARBONATE DEHYDRATASE; PHENYTOIN; SODIUM CHANNEL; TOPIRAMATE;

ANOREXIA; ANTICONVULSANT ACTIVITY; ATAXIA; CLINICAL TRIAL; CONCENTRATION LOSS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FOCAL EPILEPSY; GABAERGIC TRANSMISSION; GASTROINTESTINAL TRACT; GENERALIZED EPILEPSY; HUMAN; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; VERTIGO; VISUAL DISORDER;

EID: 0031126348     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0124     Document Type: Article

References (119)

1. Andrews CO, Fischer JH. Gabapentin: A new agent for the management of epilepsy. Ann Pharmacother. 28:1994;1188-1196.
2. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 41:1991;889-926.
3. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs. 43:1992;873-888.
4. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 46:1993;409-427.
5. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 46:1993;152-176.
6. Levy RH, Mattson RH, Meldrum B. Antiepileptic Drugs. 1995;Raven Press, New York.
7. Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs. 45:1993;1041-1065.
8. Perucca E. The clinical pharmacology of the new antiepileptic drugs. Pharm Res. 28:1993;89-106.
9. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 45:1993;760-787.
10. Pisani F, Perucca E, Avanzini A, Richens A. New Antiepileptic Drugs. 1991;Elsevier, Amsterdam.
11. Richens A, Perucca E. Clinical pharmacology and medical treatment. A Textbook of Epilepsy. 1993;Churchill-Livingstone, Edinburgh.
12. Ben-Menachem E. Levy RH, Mattson RH, Meldrum BS. Potential antiepileptic drugs: Topiramate. 1995;Raven Press, New York.
13. Gardocki JF, Labinsky LS, Brown GL, Maryanoff BE. Anticonvulsant activity of McN-4853 (M)1,3:4,5-bis-O-(LD. Epilepsia. 27:1986;648-649.
14. Maryanoff BE, Margul BL. Topiramate. Drugs of the Future. 14:1989;342-344.
15. Maryanoff BE, Nortez SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl-sulfamates in 2,3: 4,5-bis-O-(1-methylethylidene)-beta-D. J Med Chem. 30:1987;880-887.
16. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 35:1994;450-460.
17. Kimishima K, Wang Y, Tanabe K. Anticonvulsant activities and properties of topiramate. Jpn J Pharmacol. 58 (suppl 1):1992;1-472.
18. Nakamura J, Tamura S, Kanda T, Ishii A, Ishihara K, Serikawa Y, Yamada J, Sasa M. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol. 24:1994;83-89.
19. Wauquier A, Zhou S. Topiramate: A potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 24:1996;73-77.
20. Shank RP. Preclinical profile of topiramate, a novel anticonvulsant. Adv AED Ther. 1:1995;1-16.
21. Millichap JG, Thatcher LD, Williams PM. Anticonvulsant action of acetazolamide, alone and in combination with ammonium chloride. Fed Proc. 14:1955;370-371.
22. Koch A, Woodbury DM. Effects of carbonic anhydrase inhibition on brain excitability. J Pharmacol Exp Ther. 122:1958;33-342.
23. Shank RP, Vaught JL, Raffa RB, Maryanoff BE. Investigation of the mechanism of topiramate's anticonvulsant activity. Epilepsia. 32:1991;7-8.
24. Coulter DA, Sombati S, De Lorenzo R. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia. 34 (suppl 2):1993;123-123.
25. 2+. Epilepsia. 36 (suppl 4):1995;38-38.
26. Avoli M, Kawasaki H, Zona C. Effects induced by topiramate on sodium electrogenesis in mammalian central neurons. Epilepsia. 37 (suppl 4):1996;51-52.
27. Yaari Y, Selzer ME, Pincus JH. Phenytoin: Mechanisms of its anticonvulsant action. Ann Neurol. 20:1986;171-184.
28. Brown SD, Wolf HH, Swyniard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 34 (suppl 2):1993;122-123.
29. White HS, Brown SD, Skeen GA, Twyman RE. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons. Epilepsia. 36 (suppl 4):1995;34-34.
30. Gordey M, Delorey TM, Olsen RW. Topiramate modulates GABA receptor responses in Xenopus oocytes expressing several recombinant receptor subunit combinations. Epilepsia. 36 (suppl 4):1995;48-48.
31. Severt L, Coulter DA, Sombati S, De Lorenzo RJJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia. 36 (suppl 4):1995;38-38.
32. Kanda T, Nakamura J, Kurokawa M, Tamura S, Ishii A, Ishihara K, Serikawa T, Yamada J, Sasa M. Inhibition of excessive releases of excitatory aminoacids in hippocampus of spontaneously epileptic rat (SER) by topiramate (KW-6485). Jpn J Pharmacol. 58 (suppl 1):1992;92-92.
33. Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE, McComsey DF. Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther. 242:1987;74-84.
34. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on Topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 31:1996;29-46.
35. Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J Clin Pharmacol. 34:1994;1029-1029.
36. Doose DR, Gisclon LG, Liao S, Wu WN. Pharmacokinetics of topiramate. Adv Antiepil Drug Ther. 1:1995;7-16.
37. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia. 29:1988;662-662.
38. Takahashi A, Kasahara T, Sugiyama T, Sakai T, Kobayashi S, Murasaki M. Phase I study of topiramate in Japanese subjects. Epilepsia. 36 (suppl 3):1995;149-149.
39. Perucca, E, Doose, DR, The clinical pharmacokinetics of topiramate, a new antiepileptic drug, J Clin Pharmacol, (in press).
40. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia. 37 (suppl 2):1996;8-13.
41. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 37:1996;774-780.
42. Doose DR, Scott VV, Margul BL, Marriott TB, Nayak RK. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia. 29:1988;662-662.
43. Gisclon LG, Curtin CR, Kramer LD, Sachdeo RC, Levy RH. Steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia. 35 (suppl 8):1994;54-54.
44. Floren KL, Graves NM, Leppik IE. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate. Epilepsia. 30:1989;646-646.
45. Reife RA, Pledger G, Doose D, Lim P, Ward C. Topiramate: PK/PD analyses. Epilepsia. 36 (suppl 3):1995a;152-152.
46. Rosenfeld WE, Doose DR, Walker SA, Schaefer P, Reife RA. The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Poster presented at the 21st International Epilepsy Congress, Sydney, 3-8 September 1995. 3-8 September 1995;International Epilepsy CongressSydney, 3-8 September 1995, Sydney.
47. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM. The Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400 and 600mg daily dosages. Neurology. 46:1996;1684-1690.
48. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. The Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000mg daily dosages. Neurology. 46:1996;1678-1683.
49. Rosenfeld WE, Abou-Khalil B, Morrell M, Reife R, Pledger G, Hayden R. Double-blind placebo-controlled trial of topiramate adjunctive therapy for partial-onset therapy. Epilepsia. 37 (suppl 4):1996;5-5.
50. Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger Gand, The Topiramate YF/YG Study Group. Placebo controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy. Epilepsia. 37 (suppl 5):1996;153-153.
51. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 37:1996;539-543.
52. -1. Epilepsia. 36 (suppl 3):1995;149-150.
53. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, Dam M, Reife R, Pledger G, Karim R. Double-blind, placebo controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 37:1996;763-768.
54. Reife RA, Pledger GW. Clinical efficacy of topiramate: US and European experience. Adv AED Ther. 1:1995;17-23.
55. Pledger G, Reife RA, Lim P. Topiramate: Intent-to-treat and other analyses. Epilepsia. 37 (suppl 4):1996;72-72.
56. Reife RA, Pledger G, Lim P, Karim R. Topiramate: Pooled analysis of six placebo-controlled trials. Epilepsia. 37 (suppl 4):1996;74-74.
57. Ben-Menachem E. Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia. 36 (suppl 3):1995;152-152.
58. Binelli S, Avanzini G, Canafoglia L, Di Fazio M. Long-term, open-label study of topiramate in 15 patients with difficult-to-control epilepsy. Epilepsia. 37 (suppl 4):1996;60-60.
59. Canger R, Guidolin L, Di Fazio M. Topiramate in the treatment of partial refractory partial epilepsy: An open-label study with long-term follow-up. Epilepsia. 37 (suppl 4):1996;61-61.
60. Cowell PG, Coles HJ, Crawford PM. Topiramate as adjunctive therapy in patients with refractory epilepsy: A report of long-term, open-label study. Epilepsia. 36 (suppl 3):1995;152-152.
61. Durisotti C, Garofalo P, Di Fazio M. Topiramate as add-on, open therapy in drug-resistant epilepsies: One year of follow-up. Epilepsia. 37 (suppl 4):1996;89-89.
62. Engelskjon T, Ohannessen SI, Kloster R, Nakken KO, Lossius R, Henriksen O. Long-term effect of topiramate in refractory partial epilepsy. Epilepsia. 34 (suppl 2):1993;123-123.
63. Fincham RW, Schottelius D. Long-term therapy with topiramate in patients with partial seizures. Epilepsia. 36 (suppl 4):1995;56-56.
64. Guberman A, Bruni J, Schneiderman J, Couture M. Canadian long-term experience with topiramate. Epilepsia. 37 (suppl 4):1996;67-67.
65. Kugoh T, Hosokawa K. Topiramate as add-on open therapy in patients with partial seizures. Epilepsia. 36 (suppl 3):1995;151-151.
66. Leuf G, Bauer G. Topiramate in drug-resistant partial and generalized epilepsies. Epilepsia. 37 (suppl 4):1996;69-69.
67. Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory epilepsy: A 2-year long-term follow-up. Epilepsia. 37 (suppl 4):1996;70-71.
68. Mikkelsen M, Ostergaards L, Dam M. Topiramate as long-term treatment in refractory partial epilepsy. Epilepsia. 34 (suppl 2):1993;123-123.
69. Pavkovic I, Sackellares C, Beydoun A. Efficacy and safety of topiramate in epilepsy. Epilepsia. 36 (suppl 4):1995;55-55.
70. Privitera M. Long-term efficacy and safety of topiramate. Epilepsia. 36 (suppl 3):1995;152-152.
71. Proest G, Steinboff S, Ried S, Scheuler W, Ott B. Open add-on trial with topiramate (Topamax) in patients with partial epilepsy. Epilepsia. 36 (suppl 3):1995;151-151.
72. Rangel R, Penry JK, Wilder BJ, Riela A, Margul BL. Topiramate: A new antiepileptic drug for complex partial seizures. First use in epileptic patients. Neurology. 38 (suppl 1):1988;234-234.
73. Rak IW, Isacoff JM. Topiramate (Topamax) add-on therapy in medically intractable epilepsy: Clinical features of cognitive effects. Epilepsia. 34 (suppl 6):1993;44-44.
74. Tartara A, Sartori I, Manni R, Galimberti CA, Di Fazio M, Perucca E. Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial. Ital J Neurol Sci. 17:1996;429-432.
75. Walker M, Sharief MK, Sander JWAS, Patsalos PN, Shorvon SD. Double-blind placebo-controlled trial of topiramate in refractory partial epilepsy with open-label continuation. Epilepsia. 37 (suppl 4):1996;80-80.
76. Canger R, Avanzini G, Tartara A, Durisotti C, Guidolin L, Binelli S, Canafoglia L, Sartori L, Garofalo P, Di Fazio M, Cicogna C, Bertelletti D, Perucca E. Efficacia e tollerabilita' di topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico. Boll Lega It Epil. 95/96:1996;251-253.
77. Espe-Lillo J, Ritter FJ, Frost M, Spiegel RH, Reife R. Topiramate in childhood epilepsy: Titration, adverse events, and efficacy in multiple seizure types. Epilepsia. 36 (suppl 4):1995;56-56.
78. Sachdeo R, Kugler S, Wenger E, Mandelbaum D. Topiramate in Lennox-Gastaut syndrome. Epilepsia. 37 (suppl 4):1996;118-119.
79. Rossounis S, Da Costa A. Topiramate in childhood minor epileptic status. Epilepsia. 37 (suppl 4):1996;75-75.
80. Glauser TA, Olberding P, Clark P, Reife R, Baldassarre J, Conover D. Topiramate monotherapy substitution in children with partial epilepsy. Epilepsia. 37 (suppl 4):1996;98-98.
81. Rosenfeld WE, Sachdeo RC, Wood R. Topiramate can be a successful monotherapy drug. Epilepsia. 36 (suppl 4):1995;56-56.
82. Tigaran S, Dam M. Topiramate monotherapy: Patient with refractory complex partial seizures becomes seizure-free. Epilepsia. 37 (suppl 4):1996;62-63.
83. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia. 38:1997;294-300.
84. Shorvon SD. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia. 37 (suppl 2):1996;18-22.
85. Reife RA, Pledger G. Safety of topiramate in clinical use. Adv AED Ther. 1:1995;24-29.
86. Reife RA, Lim P, Pledger G. Topiramate: Side effect profile in double-blind studies. Epilepsia. 36 (suppl 4):1995;34-34.
87. Perucca E. Anticonvulsant drugs. Aronson JJ, Van Boxtel CJ. Side Effects of Drugs Annual 18. 1994;Elsevier Science B.V. Amsterdam.
88. Wasserstein AG, Rak I, Reife RA. Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: Examination of urine and plasma constituents. Epilepsia. 36 (suppl 3):1995;153-153.
89. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia. 36 (suppl 3):1995;153-153.
90. Schear MJ, Rowan AJ, Wiener JA, Haug SJ, Mindel JS. Drug-induced myopia: A transient side effect of topiramate. Epilepsia. 31:1990;643-643.
91. Thanedar S, Rosenfeld WE, Doose D. Topiramate well tolerated by pediatric patients. Epilepsia. 36 (suppl 4):1995;34-34.
92. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia. 37 (suppl 2):1996;14-17.
93. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy. Epilepsia. 35 (suppl 8):1994;54-54.
94. Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo controlled trials in outpatients with partial seizures. Epilepsia. 36 (suppl 3):1995;158-158.
95. Levy RH, Bishop F, Streeter AJ, Trager WF, Kunze KL, Thummel KT, Mather GG. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia. 36 (suppl 4):1995;47-47.
96. Sachdeo RC, Sachdeo SK, Levy RH, Nayak RK, Kramer LD, Gisclon LG. Topiramate and phenytoin pharmacokinetics in patients with epilepsy during monotherapy and combination therapy. Epilepsia. (in press):1997.
97. Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, Nayak RK. Comparison of the steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 38:1997;324-333.
98. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 38:1997;317-323.
99. Stahle, PL, Stellar, SM, Lucas, PN, Desai, DM, Takacs, AR, 1994, Topiramate-warfarin interaction in the dog, Abstract, Eastern Regional Meeting of the American Association of Pharmacologists.
100. Liao SS, Palmer M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res. 11 (suppl):1994;444-444.
101. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Brit J Clin Pharmacol. 27 (suppl 1):1989;101-107.
102. Penry JK, Wilder BJ, Sachdeo RC, Vaughan LU, Ahlbrandt RA, Sommerville KL, Sussman NM, Yerby MS, Willmore LJ, Wilensky AJ, Treiman DM, Mattson RH, Laxer KD, Kramer RE, Kuzniecki R, Gallagher BB, Faught RE, Dreifuss FE, Drake ME. Multicentre dose-response study of vigabatrin in adults with focal (partial) epilepsy. Epilepsia. 34 (suppl 6):1993;67-67.
103. -1. Neurology. 46:1996;54-61.
104. Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Bauer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res. 15:1993;67-73.
105. Brodie M. Lamotrigine. Lancet. 339:1992;1397-1400.
106. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG, for the US Lamotrigine Protocol 05 Clinical Trial Group. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology. 43:1993;2284-2291.
107. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, Cooper G, Sahlroot T, Sheridan P, Ashworth M, Lee SI, Sierzant TL. Felbamate for partial seizures: Results of a controlled clinical trial. Neurology. 41:1991;1785-1789.
108. Theodore WH, Raubertas RF, Porter RJ, Nice FJ, Devinsky O, Reeves P, Bromfield E, Ito B, Balsih M. Felbamate: A clinical trial for complex partial seizures. Epilepsia. 32:1991;392-397.
109. Anonymous. Felbamate. A Novel Antiepileptic Agent. 1993;Churchill Radius, Clifton.
110. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 36 (suppl 6):1995;14-21.
111. Brown TR. Efficacy and safety of gabapentin. Chadwick D. New Trends in Epilepsy Management: The Role of Gabapentin. 1993;Royal Society of Medicine, London.
112. Chadwick D, Marson T, Kadir Z. The clinical use of new antiepileptic drugs. An overview of safety and efficacy. Epilepsia. 37 (suppl 6):1996;17-22.
113. Perucca E. Recipes for clinical practice. Trimble MR. An Appraisal of Some New Anticonvulsants-A Clinical Perspective. 1994;John Wiley and Sons, Chichester.
114. Perucca E. The new generation of antiepileptic drugs: Advantages and disadvantages. Brit J Clin Pharmacol. 42:1996;531-543.
115. Perucca E. Evaluation of drug treatment outcome in epilepsy: A clinical perspective. Pharmacy World and Science. (in press):1997.
116. Rosenfeld WE, Holmes GB, Hunt TL, Schaefer P. Topiramate. Effective dosaging enhances potential for success. Epilepsia. 33 (suppl 3):1992;118-118.
117. Biton V, Montouris G, Edwards K, Kamin M. Comparison of two upward titration rates in initiation of therapy with topiramate. Epilepsia. 37 (suppl 4):1996;5-5.
118. Ben-Menachem, E, 1996, Preliminary results with topiramate in primary generalized seizures, Topiramate: Closing the Therapeutic Gap in Epilepsy. Satellite Symposium, Second European Congress of Epileptology, 3 September, European Congress of Epileptology, The Hague.
119. Biton V, Reife R, Kamin M, Bobrovski K. Topiramate (Topamax) as add-on therapy in primary generalized epilepsy. Neurology. 46:1996;A176-A176.